Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gentium files for US approval of pig DNA product defibrotide in hepatic VOD

This article was originally published in Scrip

Executive Summary

Italian biopharmaceutical company Gentium has submitted an NDA to the US FDA for its lead compound, defibrotide, for the treatment of hepatic veno-occlusive disease (VOD) in adults and children undergoing haematopoietic stem cell transplantation (HSCT). The product, which is the sodium salt of a complex mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA, has been granted fast track status for the treatment of severe VOD in recipients of stem cell transplants by the US regulator and if approved, could become the first drug approved for this indication. Defibrotide also has orphan drug designation for severe VOD in this market.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC013602

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel